Polypeptides for inducing a protective immune response against
View Patent ↗The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 or a fragment thereof, S. aureus AhpC-AhpF compositions, and uses of such polypeptides and compositions. SEQ ID NO: 1 has a full length S. aureus AhpC sequence. A derivative of SEQ ID NO: 1 containing an amino His-tag and three additional carboxyl amino acids was found to produce a protective immune response against S. aureus . MGHHHHHHHHHHSSGHIEGRH MSLINKEILPFTAQAFDPKKDQFKEVTQE DLKGSWSVVCFYPADFSFVCPTELEDLQNQYEELQKLGVNVFSVSTDTHF VHKAWHDHSDAISKITYTMIGDPSQTITRNDVLDEATGLAQRGTFIIDPD GVVQASEINADGIGRDASTLAHKIKAAQYVRKNPGEVCPAKWEEGAKTLQ PGLDLVGKI AEQ
1. A purified polypeptide immunogen comprising an amino acid sequence with up to 9 amino acid alterations from SEQ ID NO: 1, wherein said polypeptide provides protective immunity against S. aureus , and wherein said polypeptide immunogen is not the polypeptide of SEQ ID NO: 1.
2. The polypeptide immunogen of claim 1 , wherein said polypeptide is substantially purified.
3. The polypeptide immunogen of claim 1 , wherein said amino acid sequence differs from SEQ ID NO: 1 by up to 5 amino acid alterations.
4. The polypeptide immunogen of claim 3 , wherein said polypeptide is substantially purified.
5. The polypeptide immunogen of claim 3 , wherein said amino acid sequence differs from SEQ ID NO: 1 by up to 3 amino acid alterations.
6. The polypeptide immunogen of claim 5 , wherein said polypeptide is substantially purified.
7. The polypeptide immunogen of claim 1 , wherein said polypeptide consists of amino acids 22-213 of SEQ ID NO: 2.
8. The polypeptide immunogen of claim 7 , wherein said polypeptide is substantially purified.
9. A composition able to induce a protective immune response in a patient comprising an immunologically effective amount of the polypeptide immunogen of claim 1 and a pharmaceutically acceptable carrier.
10. A composition able to induce a protective immune response in a patient comprising an immunologically effective amount of the polypeptide immunogen of claim 3 and a pharmaceutically acceptable carrier.
11. A composition able to induce a protective immune response in a patient comprising an immunologically effective amount of the polypeptide immunogen of claim 5 and a pharmaceutically acceptable carrier.
12. An immunogen comprising a polypeptide consisting of an amino acid sequence with up to 9 amino acid alterations from SEQ ID NO: 1, wherein said polypeptide provides protective immunity against S. aureus , and one or more additional regions or moieties covalently joined to said amino acid sequence at the carboxyl terminus or amino terminus, wherein each region or moiety is independently selected from a region or moiety having at least one of the following properties: enhances the immune response, facilitates purification, or facilitates polypeptide stability.
13. The immunogen of claim 12 , wherein said polypeptide differs from SEQ ID NO: 1 by up to 5 amino acid alterations.